A PK-PD Study of PSN821 in Type 2 Diabetes Patients (T2DM)
Status:
Completed
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the pharmacokinetics and pharmacodynamics of
PSN821 in patients with type 2 diabetes.
Subjects will be assessed for beta-cell function using a hyperglycaemic clamp before the
start of treatment and at the end of a 12 week treatment period as the primary endpoint.
HbA1c, fasting plasma glucose and body weight are secondary endpoints.